3d systems announces vsp® bolus to optimize radiotherapy targeting, improve patient experience

Rock hill, s.c., april 21, 2022 (globe newswire) -- today, 3d systems (nyse:ddd) announced its entry into the radiation oncology market with fda 510(k) clearance of vsp ® bolus, a solution designed to deliver high-quality patient-specific radiotherapy treatment accessories. as the latest addition to the company's vsp portfolio of personalized medical devices, vsp bolus is the only solution on the market that offers a full design and production service based on the patient's treatment plan. as a result, radiotherapy providers do not need specialized design software and expertise, allowing them to focus directly on patient treatment and care. 3d systems' deep experience in additive manufacturing of medical devices enables the company to deliver 3d-printed, biocompatible patient-specific boluses that can improve therapy modulation as well as patient comfort.
DDD Ratings Summary
DDD Quant Ranking